胚系DDX41变异易感髓系肿瘤的遗传图谱
该研究分析了9821例无亲缘关系患者中176例携带82种推定胚系DDX41变异的血液系统恶性肿瘤患者的基因组图谱。采用DDX41特异性变异分类,比较116例携带因果变异(CV)与60例携带意义不确定变异(VUS)患者的特征。CV组患者年龄较大(中位69岁)、男性占优、常合并体细胞DDX41变异、体细胞突变负荷较低,且AML/MDS患者总生存期更优。
要点
- 胚系DDX41 CV患者中位年龄69岁,男性占74%,常合并体细胞DDX41变异(79%)。
- CV组体细胞突变负荷为1.4±0.1,低于VUS组的2.9±0.04(P=.012)。
- CV组AML/MDS患者总生存期优于VUS组,且独立于原始细胞计数、异常核型和合并变异。
核心结论
- 胚系DDX41变异定义了一个独特的临床实体,其因果变异图谱和血液系统恶性肿瘤表型谱得到扩展。
- 研究强调了制定基因特异性诊断和临床管理指南的迫切需求。
研究设计与样本
- 研究分析了9821例无亲缘关系患者中176例携带82种推定胚系DDX41变异的血液系统恶性肿瘤患者的基因组图谱。
- 采用研究者提出的DDX41特异性变异分类,将患者分为116例携带因果变异(CV)和60例携带意义不确定变异(VUS)两组。
主要发现
- CV组患者年龄较大(中位69岁),男性占74%,VUS组男性占60%(P=.03)。
- CV组合并体细胞DDX41变异者占79%,VUS组占5%(P<.0001)。
- CV组体细胞突变负荷为1.4±0.1,VUS组为2.9±0.04(P=.012)。
- CV组AML患者中NPM1、CEBPA和FLT3等经典重现性遗传学异常近乎缺失。
- CV组AML/MDS患者总生存期优于VUS组,且该优势独立于原始细胞计数、异常核型和合并变异(包括TP53),不受患者性别、年龄或特定胚系CV影响。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Germline DDX41 variants are the most common mutations predisposing to acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) in adults, but the causal variant (CV) landscape and clinical spectrum of hematologic malignancies (HMs) remain unexplored. Here, we analyzed the genomic profiles of 176 patients with HM carrying 82 distinct presumably germline DDX41 variants among a group of 9821 unrelated patients. Using our proposed DDX41-specific variant classification, we identified features distinguishing 116 patients with HM with CV from 60 patients with HM with variant of uncertain significance (VUS): an older age (median 69 years), male predominance (74% in CV vs 60% in VUS, P = .03), frequent concurrent somatic DDX41 variants (79% in CV vs 5% in VUS, P < .0001), a lower somatic mutation burden (1.4 ± 0.1 in CV vs 2.9 ± 0.04 in VUS, P = .012), near exclusion of canonical recurrent genetic abnormalities including mutations in NPM1, CEBPA, and FLT3 in AML, and favorable overall survival (OS) in patients with AML/MDS. This superior OS was determined independent of blast count, abnormal karyotypes, and concurrent variants, including TP53 in patients with AML/MDS, regardless of patient's sex, age, or specific germline CV, suggesting that germline DDX41 variants define a distinct clinical entity. Furthermore, unrelated patients with myeloproliferative neoplasm and B-cell lymphoma were linked by DDX41 CV, thus expanding the known disease spectrum. This study outlines the CV landscape, expands the phenotypic spectrum in unrelated DDX41-mutated patients, and underscores the urgent need for gene-specific diagnostic and clinical management guidelines.
引用
- Li P, Brown S, Williams M, et al. The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms. Blood. 2022. PMID: 35671390. doi:10.1182/blood.2021015135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。